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Critical roles of specimen type and temperature before
and during fixation in the detection of phosphoproteins
in breast cancer tissues
Sibylle Gündisch1,5, Laura Annaratone2,5, Christian Beese1, Enken Drecol1, Caterina Marchiò2,3, Elena Quaglino4,
Anna Sapino2,3, Karl-Friedrich Becker1 and Gianni Bussolati2
The most efficient approach for therapy selection to inhibit the deregulated kinases in cancer tissues is to measure their
phosphorylation status prior to the treatment. The aim of our study was to evaluate the influence of pre-analytical
parameters (cold ischemia time, temperature before and during tissue fixation, and sample type) on the levels of proteins
and phosphoproteins in breast cancer tissues, focusing on the PI3 kinase/AKT pathway. The BALB-neuT mouse breast
cancer model expressing HER2 and pAKT proteins and human biopsy and resection specimens were analyzed. By using
quantitative reverse phase protein arrays (RPPA), 9 proteins and 16 phosphoproteins relevant to breast cancer biology
were assessed. Cold temperatures before and during fixation resulted in a marked improvement in the preservation of the
reactivity of biological markers (eg, ER, HER2) in general and, specifically, pHER2 and pAKT. Some phosphoproteins,
eg, pHER2 and pAKT, were more sensitive to prolonged cold ischemia times than others (eg, pS6RP and pSTAT5).
By comparing the phosphoprotein levels in core needle biopsies with those in resection specimens, we found a
marked decrease in many phosphoproteins in the latter. Cold conditions can improve the preservation of proteins and
phosphoproteins in breast cancer tissues. Biopsies≤ 1 mm in size are the preferred sample type for assessing the
activity of deregulated kinases for personalized cancer treatments because the phosphoprotein levels are better preserved
compared with resection specimens. Each potential new (phospho)protein biomarker should be tested for its sensitivity
to pre-analytical processing prior to the development of a diagnostic assay.
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In the era of personalized therapies, a precise assessment of
biomarkers, both at the protein and gene levels, is crucial for an
optimal patient management.1 This is especially true for breast
cancer, where treatment is determined according to the levels
of immunohistochemical (IHC) expression of hormone
receptors and HER22 evaluated in formalin-fixed and
paraffin-embedded (FFPE) tissues. However, variations in
tissue processing affect the preservation of antigenic sites,
preventing a reproducible measurement of proteins and
phosphorylated epitopes.
Studies on the accuracy of the analytical results have
highlighted the impact of a range of variables related to the
pre-analytical phase before the molecular test is performed.3–6
Although a large number of variables potentially affect the
tissue quality,7 recent studies have shown that cold ischemic
time (ie, time from tissue removal to formalin fixation)8,9 and
temperatures during fixation processes10,11 are crucial.12,13
These parameters are particularly critical (also in terms of
clinical impact) for the analysis of HER2 levels3 and for
maintaining the antigenicity of phosphorylated proteins.3,14,15
In our experience, the temperature of tissue fixation may
affect the preservation of biomarkers as well. This concept is
consistent with the definite advantages offered by the
preservation of fresh (ie, not fixed) surgical specimens with
vacuum packing and cooling (VPAC) at 4 °C as experienced
and routinely practiced in our hospital.16–18 We have shown
that fresh tissues kept vacuum sealed at 4 °C during transfer
from the surgical theatre to the pathology laboratory are
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optimally preserved for the primary cell cultures18 and
maintain the integrity of nucleic acids (DNA and RNA).19
In recent studies, it has also been shown that the fixation of
VPAC tissues in cold formalin (4 °C) followed by ethanol at
4 °C guarantees an acceptable histology, a better preservation
of RNA compared with the standard formalin fixation,11
possibly by slowing down the enzymatic activity, and an
optimal preservation of antigens for IHC analyses.10,20
However, the definition of the impact of the pre-analytical
variables on protein preservation is rather controversial, in
part because of the semi-quantitative nature of IHC scoring.
A quantitative extraction-based measurement of protein
biomarkers in tissues would most likely be more precise,
although the correlation between protein abundance and
histology is lost.21
In this study, we have taken advantage of a well-defined
model of breast cancer, the BALB-neuT mouse. All BALB-
neuT females are genetically pre-destined to develop, at 100%
penetrance, multiple, uniform, and small mammary tumors
expressing HER2 and pAKT proteins at high levels.22 Notably,
mammary carcinogenesis in BALB-neuT mice displays
consistent, stepwise and directly age-related progression that
mimics several features of the human breast cancer.23,24 The
multiple cancers over-expressing rat neu protein25 and the
phosphorylated form of AKT22 arise at ~ 3 months of age, and
their subcutaneous location allows a fast collection and
processing under different experimental conditions.
Using this model and thus a series of biologically identical
tumors, we have performed a series of experiments to
evaluate the combined and relative effect of time and
temperature before and during fixation on the preservation
of biomarkers in breast cancer. Protein biomarkers of interest
(eg, HER2 and several phosphoproteins) were examined with
an extraction-based quantitative evaluation methodology,
namely reverse phase protein arrays (RPPA). In parallel,
and to assess the clinical and diagnostic value of the data
accrued in the experimental model, studies were conducted in
a series of human breast cancers, both in core biopsies and
related surgical specimens fixed in formalin either using
standard conditions or following a cold formalin protocol.
MATERIALS AND METHODS
Standard Fixation (SF) Procedure
Samples (4 mm thick) were fixed for 24 h in 4% neutral-
buffered formalin (NBF) (Histo-Line Laboratories, Milan,
Italy) at room temperature (RT), routinely processed for
paraffin embedding with an automatic processor (Leica ASP
300, Leica Microsystems, Wetzlar, Germany) and embedded
in paraffin wax (FFPE).
Cold Fixation (CF) Procedure
Samples were immersed in precooled 4% NBF (Histo-Line
Laboratories, Milan, Italy) at 4 °C for 24 h (using the
ColdFIXs apparatus by Milestone Srl, Bergamo, Italy).
Thereafter, the specimens were transferred to ethanol 95%
at 4 °C for 4 h to keep enzyme activity inhibited during the
time of ethanol penetration.11 The tissues were processed for
paraffin embedding by using the same processor (Leica ASP
300, Leica Microsystems, Wetzlar, Germany) and following
the same program used for the standard FFPE, but skipping
the first 95% ethanol step.
Mouse Samples
BALB-neuT male mice25 from Biogem (Ariano Irpino, Italy)
were crossed with BALB/c female mice purchased from
Charles River Laboratories (Calco, Italy). The progeny was
genotyped to discriminate between wild type BALB/c and
BALB-neuT females heterozygous for the neu transgene.
All mice were bred under specific pathogen-free conditions
(Allentown Caging Equipment, Allentown, NJ, USA) at the
Molecular Biotechnology Center (Torino, Italy) and
treated according to the European Guidelines and
policies, as approved by the University of Torino Ethical
Committee. To assess mammary tumor growth, BALB-neuT
females were inspected weekly by palpation, and progressively
growing masses with a mean diameter of 41 mm were
considered tumors. Growth was monitored until all ten
mammary glands displayed a tumor or until a tumor
exceeded a mean diameter of 10 mm, time at which the mice
were sacrificed.
Immediately after excision, six tumor samples were
cut at 4-mm thick and directly fixed in formalin at RT
(standard formaline (SF)) or at 4 °C (CF) and paraffin-
embedded. To evaluate the effect of cold ischemia, 57
samples were stored at RT or at 4 °C for different times up
to 24 h and then cut at 4 mm and either fixed following SF or
CF before paraffin embedding (Figures 1a and 2a and b). Each
of the different experimental steps was performed in
triplicate.
Human Samples
The study was approved by the ‘Comitato per l’utilizzo dei
campioni biologici di derivazione umana—Comittee for
human Biospecimen Utilization (DSM-ChBU), of the
Department of Medical Sciences, University of Turin, Italy.
Written informed consent was obtained from all patients for
their tissue to be used in research.
Human breast cancer specimens were collected from the
Pathology Service of the Azienda Ospedaliera Universitaria
Città della Salute e della Scienza di Torino, Italy. Pre-surgical
core biopsies of invasive breast cancer of no special type (IC-
NST) obtained from six different patients were immediately
fixed in SF before paraffin embedding. Following the VPAC
procedure (Tissue-Safes, Milestone Srl) allowed for routine
use in our hospital for surgical specimens transfer,17 the
matched resection specimens of breast cancers were stored
under vacuum in a fridge at 4 °C till grossing. Two samples of
each surgical specimen were then fixed in parallel in SF (total
of six samples) and in CF (total of six samples) and then
paraffin embedded (Figures 1b and 2c and d).
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In addition to the histological examination for diagnosis, all
cases underwent IHC evaluation for estrogen (ER) (rabbit
mAb, clone SP1, Ventana-Diapath, Tucson, AZ) and
progesterone receptors (PgR) (rabbit mAb, clone 1E2,
Ventana-Diapath) and HER2 expression. HER2 status was
evaluated by using the Herceptest (Kit Dako). Equivocal
(score 2+) cases were investigated by FISH assay (Vysis,
Downers Grove, IL, USA). Assessment of IHC results of
hormone receptor and HER2 was performed according to the
ASCO/CAP guidelines.26,27
The hematoxylin & eosin (H&E) staining of each tissue
specimen (mouse and human) was evaluated by experienced
pathologists from the University of Turin (GB) and the
Institute of Pathology of the Technische Universität München
(ED). Tumor areas were marked for manual dissection and
areas with necrosis were excluded. The tumor cell content was
at least 80% in the resection specimens and 20–80% in the
core needle biopsies.
Protein Extraction
Proteins from FFPE tissues were extracted using the
Qproteome FFPE Tissue Kit (Qiagen GmbH, Hilden,
Germany) as previously described.28 Briefly, 10-μm FFPE
tissue sections were deparaffinized, and proteins were
extracted by using EXB Plus buffer (Qiagen GmbH, Hilden,
Germany), which was supplemented with protease (Complete
Protease Inhibitor Cocktail), phosphatase (PhosSTOP Phos-
phatase Inhibitor Cocktail, Roche Applied Science, Mannheim,
Germany) and kinase inhibitors (staurosporine and genistein,
Sigma-Aldrich Chemie GmbH, Munich, Germany). Protein
concentration was determined by using the Bradford
protein assay (BioRad, Hercules, USA) according to the
manufacturer’s instructions. For generating protein arrays,
the concentration was adjusted to 2mg/ml. Protein lysates
were stored at − 20 °C short-term and for long-term storage
at − 80 °C.
Analysis of Protein Expression by Reverse Phase Protein
Arrays (RPPA)
RPPAs were generated by using the SpotBot Extreme micro-
arrayer according to the manufacturer’s instructions (Arrayit,
Sunnyvale, CA 94089, USA). Briefly, for every lysate and every
dilution (not diluted, 1:2, 1:4, 1:8, 1:16, buffer), two replicates
were applied onto a nitrocellulose-coated glass slide (Oncocyte
Avid Grace Bio-Labs, Bend, USA), which produced 12 data
points per sample. These miniature dilution curves allow
analysis of each analyte/antibody combination in the linear
dynamic range.29 The slides were incubated with specific anti-
bodies (Supplementary Table 1), and proteins were visualized by
using a mixture of ECL Prime Western Blotting Detection
Reagents and ECL Advance Western Blotting Detection Kit
(Amersham/GE Healthcare Europe GmbH, Freiburg, Germany).
The developed films were scanned individually on a scanner
(Scanjet 3770, Hewlett-Packard, Hamburg, Germany) with
1200 dpi and saved as TIF files. The TIF images were analyzed
by using MicroVigene 3.5.0.0 (VigeneTech, Carlisle, USA) to
determine the background corrected intensities for each spot.
For normalization of the antibody signals, the total protein
amount was determined by staining representative slides with
SYPRO Ruby Protein Blot Stain (Molecular Probes, Eugene, OR,
USA); the representative slides were printed at the beginning or
at the end of the arraying process. SYPRO Ruby staining was
performed according to the manufacturer’s instructions and
visualized using an E-BOX VX2 UV Transilluminator (Peqlab,
Erlangen, Germany). All antibodies used in this study were
validated for specificity by western blot analysis.
In analogy to a previous study,29 in this study, the inter-
array variation between two independently spotted arrays was
determined. The average inter-array coefficient of variation
(CV) ranged between 10 and 12% (unpublished data and
Supplementary Figure 1).
Figure 1 Study design. (a) Murine breast cancer specimens were
collected. The reference samples were immediately fixed in standard
formalin (room temperature) (SF) or cold formalin (4 °C) (CF) and paraffin
embedded. The ischemia samples were stored at room temperature or
under vacuum at 4 °C during the ischemia time up to 24 h and were fixed
in either standard formalin or cold formalin before paraffin embedding.
(b) Human breast cancer specimens were collected. Biopsies were
immediately fixed in standard formalin before paraffin embedding. The
matched resection specimens were stored under vacuum at 4 °C for 20 h
before preservation and fixed either in standard formalin or cold formalin
before paraffin embedding. Proteins were analyzed by reverse phase
protein array and/or western blot analysis.
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Western Blot (WB) Analysis
Equal amounts of protein lysates (25 μg) were separated by
one-dimensional SDS-PAGE and blotted onto nitrocellulose
membranes. Protein detection was performed using anti-
p-Erk-1/2, anti-p-Akt, anti-p-HER2, and anti-beta-actin
antibodies (Supplementary Table 1). Secondary antibodies
used for RPPA and western blot analysis were anti-rabbit IgG,
HRP-linked antibody from Cell Signaling Technology
(#7074) and anti-mouse IgG, HRP-linked antibody from
GE Healthcare (NA931). Proteins were visualized by using
ECL solution. Western blot quantification was performed by
using the open source software Image J (National Institutes of
Health, USA).
Statistics
Statistical analysis of the normalized data received by RPPA
was performed by using the parametric t-test. All statistical
analyses were conducted two-sided, and a P-valueo0.05 was
considered to indicate statistical significance by using SPSS
version 22.0 (SPSS, Chicago, IL, USA).
RESULTS
Protein and Phosphoprotein Preservation of Mouse
Samples
A total of 63 mammary tumors from 31 BALB-neuT mice
were fixed in formalin and processed for paraffin embedding
(Figure 1). Histological examination showed a uniform
pattern of invasive carcinomas growing as solid nests and
clumps of cancer cells with a monotonous cytology. Scattered
foci of necrosis were only occasionally detected.
We analyzed 25 proteins of biological and clinical interest
for breast cancer, focusing our interest on the PI3 kinase/AKT
pathway (Table 1).
First, we investigated the levels of nine proteins: HER2, ER,
PgR, AKT, Cyclin D, mTOR, and Cytokeratin 18, and two
reference proteins, GAPDH and beta-Actin. In all cases, the
antibodies used (and employed for the analysis of human
samples as well; see below) showed an extensive cross-reactivity
with the mouse proteins. The HER2 protein over-expressed in
these experimental tumors was analyzed by using two reagents
commonly used for IHC evaluation in human breast cancers:
the DAKO polyclonal serum A0485 and the CB11 monoclonal
antibody Novocastra. Both reagents were reactive, and we were
thus able to establish the effect of differential experimental
conditions of cold ischemia time, temperature and fixation on
the preservation of the protein. The RPPA data indicate that the
HER2 protein, at least as detectable through the epitopes
analyzed, is relatively robust and insensitive to delayed tissue
processing, by using room or cold temperature preservation.
Signals were preserved even after several hours (up to 5) of
ischemia time, while a partial decrease was observed only when
the delay to fixation was extended to 24 h in cold conditions
(Supplementary Table 2). The polyclonal reagent gave a
stronger signal than the CB11 monoclonal antibody, and the
difference was more marked in samples processed after
prolonged ischemia time. Among the other proteins, PgR and
mTOR produced variable results, whereas the ER values were
stable across the different preservation conditions, which was
similar to those observed for HER2.
Fixation in CF, as opposed to SF, allowed a satisfactory
preservation of proteins. The difference was not statistically
significant, but a trend was observed pointing to a better
preservation fixing at 4 °C.
Next, we focused on 16 phosphoproteins, selected for their
biological and clinical relevance to breast cancer and because
they represented major signaling pathways (eg, PI3K and
MAPK pathways). Although sensitivity to ischemia was a con-
stant feature for almost all of the analyzed phosphorylated
proteins, its degree varied (Table 1, Figure 3a). Some
phosphoproteins of diagnostic interest, such as pHER2 and
pAKT, showed an extreme sensitivity, with a475% loss of the
respective signal intensity as the result of ischemic conditions.
Figure 2 Breast cancer specimens fixed alternatively in cold formalin
(a, c) or in neutral-buffered formalin at room temperature and stained
with hematoxylin & eosin. Figures a and b: breast cancer from BALB-neuT
mice. (a) Time 0 specimens, fixed in cold formalin. (b) Specimen with cold
ischemia time of 5 h at room temperature, followed by standard neutral-
buffered formalin fixation at RT. Please notice that morphology is similar
while, as shown in Figure 3, the preservation of phosphoprotein markers
is dramatically different. (c and d) Human breast carcinoma (same case),
fixed alternatively in cold formalin (c) or in formalin at room temperature
(d). The histological features are not affected by the temperature of the
fixative (magnification: 200 × ; insets in figures a and b: 400× ).
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The effect was already critical after 30min of ischemia, a
finding fitting with the challenge of human resection samples
for the detection of these markers (see below). Other
phosphoproteins (eg, pHER3, pS6RP, pSTAT3, and pSTAT5)
were instead found to be rather insensitive to ischemic
conditions (Table 1).
CF allowed a statistically significant improvement in the
preservation of ischemia-sensitive phosphoproteins, as
demonstrated by a loss of signal of 435% for pHER2,
p-p38 MAPK and pNFkB in specimens fixed in SF compared
with parallel tissues fixed in CF (see Supplementary Table 2).
This effect was quite definite at time point zero, that is,
immediately fixed after sacrifice of the animals, and was still
detectable in specimens that had been kept at 4 °C for
different times (up to 5 h). On the contrary, the ‘cold fixation
advantage’ was lost, at any time, in specimens preserved at
RT. In addition, an ischemia time at RT, even as short as
30 min, implied a loss of sensitive phosphoproteins, which
could not be restored by cold formalin processing (Table 2,
Figure 3b and c).
Protein and Phosphoprotein Preservation of Human
Samples
Out of six breast cancers, four cases were found to over-
express HER2 protein (score 3+), while two cases (cases #3
and #5) were scored 2+ and HER2 was not amplified as
determined by FISH analysis. ER was positive (values ranging
from 70 up to 99% positivity) in all but one case (case #1),
while PgR was positive in four cases and negative in two
(cases #1 and #6). The staining was performed on sections
from blocks of core biopsies and those of surgical specimens
subjected to SF and CF fixation processing, and a perfect
matching of the results was observed.
Proteins extracted from sections of each case (three
different blocks) underwent the same analytical procedures
(RPPA and WB) for the same 9 proteins and 16 phospho-
proteins as above (Table 1, Supplementary Table 3). Because
we were interested in the comparative values (and the related
effect of the different processing procedures), we set as 100%
the value observed for CB, while the value obtained with the
SF and CF material from the same case was expressed as a
percentage of the former.
No statistically significant difference, for any marker, was
observed when the results for SF vs CF tissue blocks from the
resection specimens were analyzed.
Sensitivity to ischemic conditions was therefore determined
by comparing data of CB to those obtained in the resection
specimens from the same case. Among the proteins analyzed,
only HER2 was found to be sensitive, while the other proteins
(and specifically ER and PgR) were found to be insensitive to
ischemic conditions following resection, at least in our VPAC
conditions. The sensitivity of HER2 was detected as low (25%
loss of signal in one or more resection) in samples analyzed
with the DAKO polyclonal serum and moderate (50% loss)
when the analysis was performed with the CB11 monoclonal
antibody.
The data obtained for the 16 phosphoproteins matched
those obtained for the murine samples. In Figure 4, the results
of 6 examples are shown. Some phosphoproteins (such as
pAKT, pEGFR and pPRAS40) were found to be affected by
ischemia with a loss of signal in 475% of resections, while
others were stable and not affected (eg, pSTAT5). It should be
noted that not all patients showed over-expression of the
phosphoproteins analyzed; eg, high levels of p-Akt and
p-EGFR are only seen in patients #3 and #4. In these two
patients a dramatic loss of both phosphoproteins is observed
in the resection specimens compared to the core biopsies.
DISCUSSION
The present study was performed to determine the impact of
ischemic and fixation steps on the preservation of 16
phosphoproteins and 9 total proteins that are relevant for
breast cancer. The data presented here draw significance out
of a cross-validation of results obtained in a mouse
experimental model and in human material (breast cancer
biopsies and resection specimens).
The interest in precise measurements of protein biomar-
kers, including phosphoproteins, is linked to their critical role
in predicting the evolution and response to treatment of
human tumors, an issue that is highly relevant in breast
cancer, where the therapy is currently based on the expression
levels of ER, PgR, and HER2, as well as the expression of the
proliferation marker Ki67.30–33
Recently, studies have highlighted the critical role of the
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target
of rapamycin (mTOR) pathway in mediating key functions
that determine the tumor aggressiveness,34 and new drugs
targeting activated AKT are very promising and are presently
being tested.35 Therefore, there is much interest in a reliable
determination of pAKT in cancer specimens because this is
going to be pivotal in the planning of clinical trials and the
selection of patients for treatment.
Notoriously, the preservation of tissue components is
heavily dependent on the time and conditions (eg, tempera-
ture) preceding fixation (so called cold ischemia),13,36 and
several studies have already established that the best
preservation conditions are guaranteed by immediate fixation
of histological specimens in formalin, as commonly practiced
in pre-surgical diagnostic procedures such as core biopsies for
breast cancer.37,38 However, we and others previously
reported that the temperature of the fixative is also an
important parameter to be considered.10,11
In the present experimental study, we took advantage of the
genetic predestination of female BALB-neuT mice to develop
HER2 protein39 and pAKT22 over-expressing spontaneous
invasive carcinomas at determined time points in multiple
mammary glands. By exploiting this experimental material,
we were able to assess the impact of different technical
variables (time, temperature, and fixation procedures) on the
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Table 1 Summary of protein and phosphoprotein sensitivities to ischemia in the murine and human data sets
# Protein Sensitivity to ischemia
(mouse data set)
Sensitivity to ischemia
(human data set)
1a HER2 DAKO + +
1b HER2 CB11* − ++
2 ERalpha + Not analyzable**
3 PgR ++ Not analyzable**
4 Akt − Not analyzable**
5 mTOR ++ Not analyzable**
6 Cyclin D1 + Not analyzable**
7 Cytokeratin 18 + +
8 GAPDH − −
9 beta-Actin − −
10 p-HER2 (Y1248) +++ Not analyzable**
11 p-HER3 (Y1289) + Not analyzable**
12 p-EGFR (Y1148) + +++
13 p-PTEN (S380) + Not analyzable**
14 p-Akt (S473) +++ +++
15 p-GSK3beta (S9) ++ ++
16 p-PRAS40 (T246) ++ +++
17 p-mTOR (S2448) + ++
18 p-4E-BP1 (T37/46) ++ ++
19 p-S6RP (S235/236) − −
20 p-p38 MAPK (T180/
Y182)
++ Not analyzable**
21 p-HSP27 (Ser82) not analyzable** +
22 p-Erk-1/2 (T202/
Y204)
+++ ++
23 p-NFkappaB p65
(S536)
++ Not analyzable**
24 p-STAT3 (S727) + +
25 p-STAT5 (Y694) − Not analyzable**
Mouse data set.
The results are depicted as the mean normalized signal intensities, relative to the reference sample (0 h ischemia) which was set as 100%; detailed data are
shown in Supplementary Table 2; the 24 h time point was excluded because after 24 h nearly each protein showed massive loss of signal and the other time
points are clinically more relevant.
+,≥ 25% Loss of signal in one or more ischemia samples compared with reference sample.
++,≥ 50% Loss of signal in one or more ischemia samples compared with reference sample.
+++,≥ 75% Loss of signal in one or more ischemia samples compared to reference sample.
-, Not sensitive.
*, The antibody clone CB11 against HER2 is a monoclonal antibody; the signals were in general weaker than those revealed by the DAKO polyclonal antibody.
** Protein level was too low, no quantification possible.
Bold, most ischemia sensitive proteins.
Human data set.
The results are depicted as the normalized signal intensities, relative to the reference sample (biopsy) which was set as 100% (detailed data are shown in
Supplementary Table 3).
+,≥ 25% loss of signal in one or more resection samples vs respective biopsy.
++,≥ 50% loss of signal in one or more resection samples vs respective biopsy.
+++,≥ 75% loss of signal in one or more resection samples vs respective biopsy.
-, not sensitive.
** Protein expression was too low, no quantification possible.
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preservation of protein biomarkers, including HER2 and
pAKT. A standardized study of these issues cannot con-
sistently be planned and conducted in human material,
whereas as shown here, the approach of studying tumors
from BALB-neuT mice was feasible.
Moreover, the RPPA is a reliable quantitative technology to
assess the impact of different technical variables (time,
temperature, and fixation procedures) on the preservation
of biological markers and has the potential to be incorporated
into the routine clinical workflow.40 Our approach allowed us
to transfer the results of the animal model to humans to
directly address questions of diagnostic and clinical relevance.
However, whereas the mouse cancers showed a uniform
structure consisting of nests of cancer cells making up more
than 80% of the tumors and provided fully reproducible
data, the results from the human material were less
consistent, most likely because of inter-patient variability
and discrepancies in tumor type and composition.
In the experimental model employed here, BALB-neuT
mice are transgenic for an activated form of the rat neu gene
(showing an 88% homology with the human HER2 gene)
expressed under the control of the mouse mammary tumor
virus promoter long terminal repeats (MMTV-LTR
promoter). The single-point mutation at position 664 in the
transmembrane domain of the rat neu receptor results in the
formation of homo- and heterodimers that spontaneously
transduce the proliferative signals that are responsible for the
transformation of mammary epithelial cells.25 In this experi-
mental murine model, the over-expressed HER2 protein was
fully reactive with both immunological reagents currently
employed to study HER2 expression in human breast cancer,
ie, the rabbit polyclonal serum (from DAKO) and the CB11
monoclonal antibody. This allowed us to experimentally
investigate the effect of ischemia time and temperature on the
preservation of this protein.
Consistent with previous observations by our group,12 the
preservation of HER2 protein, as quantitatively evaluated with
the RPPA procedure, was not significantly affected by the
fixation procedure (standard or cold formalin) or the length of
cold ischemia time up to 5 h, independent of the temperature
and the targeted antigen. However, the polyclonal DAKO
antiserum provided a stronger signal than the CB11 mono-
clonal antibody, and the difference was more pronounced in
samples processed after a prolonged ischemia time. This seems
Figure 3 Loss of phosphoprotein signal due to delayed preservation (murine samples). Murine breast cancer specimens were either fixed in standard
formalin or cold formalin immediately after resection or after different ischemia time points with storage until preservation at room temperature or
under vacuum at 4 °C. Protein levels were either determined by reverse phase protein arrays (a and b) or by western blot analysis (c) with the depicted
antibodies. The reverse phase protein arrays data in (a) are shown as normalized signal intensities that were calculated by normalization to total protein
(SYPRO Ruby staining). Each bar in the reverse phase protein arrays study reflects n= 3 data points, besides setting ‘cold formalin, ischemia room
temperature’, time point 5 h reflects n= 4 and time point 24 h reflects n= 1. For the setting ‘standard formalin, the ischemia room temperature’ time
point 24 h is missing because it was not analyzable. In (b), two examples (pAKT and pHER2) are highlighted showing the advantage of cold formalin if
specimens are kept at 4 °C during the cold ischemia duration. Data are shown as signal intensities in percent relative to the time point zero. Western
blot data were normalized to the reference protein beta-Actin before quantification.
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to fit with a heterogeneous sensitivity to ischemic conditions of
the different HER2 epitopes and suggests that when dealing
with breast cancers with equivocal or undefined preservation
conditions, the use of the polyclonal reagent might represent a
safer diagnostic alternative.
In the human material, similar and parallel results were
obtained when studying core biopsies and related surgical
specimens, either standard or cold fixed. Again, for HER2, the
duration of the cold ischemia time was not found to be a
critical factor, but the breast cancer specimens have routinely
been processed by using the VPAC procedure,16,17 which is
known to achieve very good preservation of biomarkers up to
several hours after surgery in breast cancer specimens.20
An important result of our study was the finding that some
phosphoproteins are more sensitive to prolonged cold
ischemia time than others. For example, pHER2 and pAKT
were very sensitive, whereas pS6RP and pSTAT5 were
relatively stable. This result is consistent with data from the
literature; Baker et al.14 and Bonnas et al.41 found a marked
reduction in pAKT in xenograft models when the cold
ischemia time was longer than 30 min. Based on comparisons
of the phosphoprotein levels in core needle biopsies and
resection specimens, we found a marked decrease in many
phosphoproteins in the resection specimens, most likely
because of the almost complete absence of a cold ischemia
time in biopsies compared with the complex processing of the
Table 2 Quantification of western blot results
Relative signal
intensity
difference
between SF vs CF
reference (CF set
as 100%)
Setting: SF, ischemia
4 °C Relative signal
intensity difference
between reference
(set as 100%) and
ischemia samples
Setting: CF, ischemia
4 °C Relative signal
intensity difference
between reference
(set as 100%) and
ischemia samples
p-Erk-1/2 38 4 24
p-Akt 24 5 27
p-HER2 34 6 39
All signal intensities of the antibodies were normalized to the reference pro-
tein β-Actin. The results of the ischemia samples are depicted as the mean
normalized signal intensity over all ischemia samples.
Figure 3 (Continued)
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surgical specimens. Surgical specimens would thus prove to be
unsuitable for an accurate measurement of many phospho-
proteins. This result, which indicates that small, pre-surgical
biopsies, as opposed to resection samples should represent the
material of choice for the detection of phosphoproteins of
diagnostic and clinical interest, such as pHER2 and pAKT, is
consistent with the study by Bai et al.,37 who used an alternative
quantitative assessment procedure. A recent study by Meric-
Bernstam et al.42 stressed the superior preservation of
phosphoprotein markers in core biopsies of breast cancer,
compared with the related resection specimens. Even the
improved preservation conditions of surgical specimens, as
currently practiced in our service through VPAC, cannot
prevent the loss of phosphoprotein epitopes because we showed
that the cooling down of large surgical specimens is a relatively
lengthy process,18 which cannot match the critical ischemia
time of o30min, as established here.
Although on one hand core biopsies seem to be more
suitable than surgical specimens to assess phosphoantigens,
on the other hand a word of caution should be voiced about
the intratumoral heterogeneity of biomarker expression in
breast cancer (such as HER2)43,44 that may not be completely
Figure 4 Loss of phosphoprotein signal due to delayed preservation (human samples). Human breast cancer biopsies from six patients were
immediately fixed in standard formalin, and matched resection specimens were either fixed in standard formalin or cold formalin. Protein expression
was determined by reverse phase protein arrays with depicted antibodies. The reverse phase protein arrays data are depicted as normalized signal
intensities, which were calculated by normalization to total protein (SYPRO Ruby staining).
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figured out by core biopsy samples. This is of particular
importance especially when large lesions have to be evaluated,
unless multiple sampling of the lesion is performed.45
The overall conclusion from our mouse and human data,
although obtained on a limited series of samples, ultimately
indicate a critical role of cold ischemia, the temperature
before and during tissue fixation, and the specimen type
(biopsy vs resection specimen) for preserving sensitive
phosphoproteins. Fixation in cold formalin, compared to
standard fixation at RT, resulted in a statistically significant
improvement in the preservation of the reactivity of pHER2
and pAKT (Figure 3a). A limit of our study is the lack of
comparison between RPPA data and IHC data, however, our
quantitative evaluation evidence is consistent with the IHC
study by Chafin et al.10 who recently showed that fixation in
cold formalin followed by a further processing with hot
fixative allows a better preservation of phosphorylated
epitopes compared to the standard procedure.
A rational interpretation of the observed data and
conclusions have to take into consideration the following
points: (i) formalin penetrates into immersed specimens at a
speed of approximately 3.6 mm in the first hour46 and (ii)
when tissues are immersed in a relatively large volume of
formalin, they achieve the temperature of the solution. These
considerations suggest that in relatively large specimens (as
here exemplified by the experimental rodent tumors),
immersion into cold formalin would result in cooling down
of the tissue temperature (and presumably an inhibition of
phosphatase activity) while the fixative is penetrating into the
tissue. Implementation of this procedure in human specimens
would imply fixation in cold formalin just a few minutes after
surgical removal, a procedure that does not appear to be easily
practical in routine practice.
In small specimens of the size of core biopsies (1 mm in
diameter), the penetration of the formalin within the threshold
time of 15min seems to provide a satisfactory preservation of
sensitive phosphorylated residues. Further improvements, such
as cold fixation of core biopsies or the use of alternative
fixatives, may be tested in future experiments.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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